<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797793</url>
  </required_header>
  <id_info>
    <org_study_id>ADBG-2043</org_study_id>
    <nct_id>NCT04797793</nct_id>
  </id_info>
  <brief_title>A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Double-blind, Randomized, Placebo Controlled Study to Compare Adapalene Gel 0.1% to Differin Gel and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate therapeutic equivalence and safety of adapalene gel 0.1% (Taro Pharmaceuticals&#xD;
      U.S.A., Inc.) and Differin® Gel (Adapalene Gel 0.1%, Galderma) in the treatment of acne&#xD;
      vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, double-blind, randomized, placebo controlled, parallel-group study, Adapalene&#xD;
      Gel 0.1% (Taro Pharmaceuticals U.S.A, Inc.) and to Differin® Gel (Adapalene 0.1%, Galderma)&#xD;
      and both active treatments to a placebo control in the treatment of acne vulgaris&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Actual">January 8, 2021</completion_date>
  <primary_completion_date type="Actual">January 8, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage change in the inflammatory and non-inflammatory lesion counts</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Demonstration of Therapeutic Equivalence</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">978</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Adapalene gel 0.1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Differin® Gel (Adapalene 0.1%, Galderma)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene Gel 0.1%</intervention_name>
    <description>The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.</description>
    <arm_group_label>Adapalene gel 0.1%</arm_group_label>
    <other_name>Test Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Control</intervention_name>
    <description>The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.</description>
    <arm_group_label>Placebo Control</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Differin® Gel (Adapalene 0.1%, Galderma)</intervention_name>
    <description>The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.</description>
    <arm_group_label>Differin® Gel (Adapalene 0.1%, Galderma)</arm_group_label>
    <other_name>Reference Product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis&#xD;
             of acne vulgaris.&#xD;
&#xD;
          -  Subjects who are 18 years of age or older (up to the age of 40) must have provided IRB&#xD;
             approved written informed consent. Subjects ages 12 to 17 years of age inclusive must&#xD;
             have provided IRB approved written assent;&#xD;
&#xD;
          -  Subjects must have a definite clinical diagnosis of acne vulgaris of severity grade 2,&#xD;
             3, or 4 as per the Investigator's Global Assessment (IGA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female Subjects who are pregnant, nursing or planning to become pregnant during study&#xD;
             participation&#xD;
&#xD;
          -  Subjects with a history of hypersensitivity or allergy to tretinoin, retinoids, or any&#xD;
             of the study medication ingredients.&#xD;
&#xD;
          -  Subjects with the presence of any skin condition that would interfere with the&#xD;
             diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis,&#xD;
             psoriasis, squamous cell carcinoma, eczema, acneiform eruptions caused by medications,&#xD;
             steroid acne, steroid folliculitis, or bacterial folliculitis).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaidoon A. Al-Zubaidy</last_name>
    <role>Study Director</role>
    <affiliation>Catawba Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catawba Research, LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

